Spinning Off Bio Business to Focus on Royalty Company: Financial Restructuring Post-Spin-Off

AnaptysBio, Inc. (NASDAQ: ANAB) filed unaudited pro forma consolidated financial statements for 2023–2025 on April 20, reflecting the spin-off of its biopharma business into the newly listed First Tracks Biotherapeutics. These statements incorporate changes in First Tracks’ financial structure and transaction accounting adjustments following its classification as discontinued operations. While they record a decrease in cash and cash equivalents, the company makes clear that these figures are not intended as a forecast of future performance.

Upon completing the spin-off, AnaptysBio distributed shares of First Tracks to existing shareholders on a one-for-one basis and refocused its own operations on managing royalties and alliance agreements for Jemperli and imsidolimab. Prior to the split, AnaptysBio also announced a $100 million (approximately KRW 135 billion) share repurchase program, outlining its plans for shareholder returns and strategic realignment post-spin-off.

Listed on the Nasdaq, AnaptysBio has built its business on an antibody platform targeting autoimmune diseases. Recently, the company has shifted its model away from in-house R&D toward revenue streams centered on royalties and partnerships. This approach aligns with a broader trend in the U.S. biopharma industry, where high-risk drug development units are frequently separated to allow the remaining companies to concentrate on royalty management and intellectual property.